Treatment of cancer cells with HDAC inhibitors can increase p53 expression and restore p53 activity [88,89,90] mainly by downregulation of MDM2 or MDM4 [91,92] or by increasing p53 acetylation [92]. Here, MDM2 is linked to cancer.